Angion Biomedica Corp.
ANGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.02 | -0.00 | 0.00 |
| FCF Yield | -66.41% | -55.73% | -78.14% | -133.11% |
| EV / EBITDA | -0.18 | 0.05 | -0.04 | -0.02 |
| Quality | ||||
| ROIC | -35.36% | -49.09% | -60.80% | -124.65% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.10 | 0.85 | 0.90 | 0.51 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -23.87% | 11.55% | 37.71% | -155.89% |
| Safety | ||||
| Net Debt / EBITDA | 1.90 | 1.64 | 1.17 | 0.40 |
| Interest Coverage | 18.88 | -52.02 | -61.00 | -66.15 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |